Anti-tumor effect of non-steroidal anti-inflammatory drugs on human ovarian cancers
- 1 December 2007
- journal article
- research article
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 13 (4) , 365-369
Abstract
Many reports have demonstrated that non-steroidal anti-inflammatory drugs (NSAIDs) suppress malignant transformation and tumor growth, and some NSAIDs are expected to be new anti-cancer agents. In this study, we examined the anti-tumor effects of the non-specific cyclooxygenase (COX) inhibitors aspirin and piroxicam, and the selective COX-2 inhibitor meloxicam on xenotransplanted ovarian cancer. Tumor growth and survival were compared in female nu/nu mice, xenografted with subcutaneous OVCAR-3 tumors or with intraperitoneal DISS tumors and treated with aspirin (200 ppm in diet, everyday), piroxicam (150 ppm in diet, everyday) or meloxicam (162 ppm in diet, everyday). Al, of the agents tested significantly suppressed the growth of OVCAR-3 tumors xenotransplanted subcutaneously as compared to the control. There was a significant difference in inhibition of OVCAR-3 tumor growth between meloxicam and aspirin treatment. Meloxicam and piroxicam treatment significantly prolonged survival of mice with malignant ascites derived from DISS cells as compared to control and aspirin treatment. Mice treated with meloxicam survived significantly longer than those treated with piroxicam. There was no significant difference in survival between control and aspirin treatment. Necropsy revealed that one of the 6 cancer-bearing mice treated with piroxicam suffered from stomach perforation. These results indicate that a selective COX-2 inhibitor produces greater anti-tumor effect against ovarian cancer than a nonselective COX inhibitor and that meloxicam may have a potential of leading to a novel therapeutic strategy against ovarian cancer.Keywords
This publication has 39 references indexed in Scilit:
- Aspirin reduces the outcome of anticancer therapy in Meth A–bearing mice through activation of AKT-glycogen synthase kinase signalingMolecular Cancer Therapeutics, 2006
- Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude miceCarcinogenesis, 2004
- Aspirin-induced inhibition of ovarian tumor cell growth2002
- Expression of Cyclooxygenase 2 Is an Independent Prognostic Factor in Human Ovarian CarcinomaThe American Journal of Pathology, 2002
- Cyclooxygenase‐2 expression during carcinogenesis in the human stomachThe Journal of Pathology, 2001
- Aspirin and Epithelial Ovarian CancerPreventive Medicine, 2001
- Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.Journal of Clinical Investigation, 1997
- Self-Promotion? Intimate Connections Between APC and Prostaglandin H Synthase-2Cell, 1996
- Growth inhibition of rat glioma cellsin vitro andin vivo by aspirinJournal of Neuro-Oncology, 1995
- Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 ratsCarcinogenesis, 1993